Popular Trials
Monoclonal Antibodies
Vedolizumab + Tofacitinib for Ulcerative Colitis
Recruiting3 awardsPhase 4
Los Angeles, California
This trial will test the effectiveness of vedolizumab+tofacitinib and vedolizumab alone in treating adults with moderate-severe UC. Participants will receive vedolizumab+tofacitinib for 8 weeks and then be monitored for response. Those who show response will receive vedolizumab alone for 44 weeks.
Benzodiazepine
Multiple Therapies for Down Syndrome Regression Disorder
Recruiting1 awardPhase 2
Los Angeles, California
This trial is testing three treatments for Down Syndrome Regression Disorder (DSRD) in people with Down Syndrome. The treatments include a calming medication, an immune-boosting blood product, and a drug that reduces immune activity. The goal is to see which treatment is safest and most effective for managing severe symptoms.
Topical Gel
AC-1101 for Granuloma Annulare
Recruiting1 awardPhase 1
New Haven, Connecticut
This trial tests a special skin-applied gel called AC-1101 on patients with Granuloma Annulare, a specific skin condition. The gel likely works by reducing inflammation or changing the immune response in the skin.
Popular Filters
Trials With No Placebo
Janus Kinase (JAK) Inhibitor
Tofacitinib for Treatment-Resistant Colitis
Recruiting1 awardPhase 2
Montreal, Quebec
This trial is testing tofacitinib, an anti-inflammatory drug, in cancer patients who have colitis due to their cancer treatment. The drug aims to reduce inflammation in the colon by blocking specific enzymes, potentially alleviating symptoms like diarrhea. Tofacitinib has been effective in treating ulcerative colitis by reducing inflammation.
Janus Kinase (JAK) Inhibitor
Oral Tofacitinib for Ulcerative Colitis in Children
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is designed to see if tofacitinib is effective in treating pediatric UC patients who have either failed or been intolerant to other treatments. The primary objective is to see if the patients go into remission after 44 weeks of treatment.
Small Molecule
Tofacitinib for Uveitis
Recruiting3 awardsPhase 2
Saint Louis, Missouri
Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.